Quidel launches rapid test for syncytial virus

By Lisa Kerner

Charlotte, N.C., Sept. 18 - Quidel Corp. launched its QuickVue RSV test after receiving clearance from the Food and Drug Administration.

The QuickVue RSV test allows for the rapid, qualitative detection of respiratory syncytial virus (RSV) using nasopharyngeal swab and aspirate specimens from patients 18 years of age and younger.

Half of all infants become infected with RSV during their first year of life and virtually all have been infected by their second year, the company said.

Quidel is a San Diego-based rapid diagnostic solutions company

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.